Kymera Therapeutics, Inc. (KYMR)
117.39
+0.11
(+0.09%)
USD |
NASDAQ |
Sep 04, 16:00
117.47
+0.08
(+0.07%)
After-Hours: 20:00
Kymera Therapeutics Research and Development Expense (Quarterly) : 117.45M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 117.45M |
| March 31, 2026 | 96.14M |
| December 31, 2025 | 81.80M |
| September 30, 2025 | 71.94M |
| June 30, 2025 | 76.30M |
| March 31, 2025 | 78.21M |
| December 31, 2024 | 69.84M |
| September 30, 2024 | 58.41M |
| June 30, 2024 | 57.30M |
| March 31, 2024 | 47.32M |
| December 31, 2023 | 52.10M |
| September 30, 2023 | 47.22M |
| June 30, 2023 | 44.87M |
| March 31, 2023 | 41.33M |
| Date | Value |
|---|---|
| December 31, 2022 | 42.32M |
| September 30, 2022 | 43.08M |
| June 30, 2022 | 40.59M |
| March 31, 2022 | 35.24M |
| December 31, 2021 | 36.84M |
| September 30, 2021 | 37.61M |
| June 30, 2021 | 34.67M |
| March 31, 2021 | 25.48M |
| December 31, 2020 | 19.90M |
| September 30, 2020 | 15.28M |
| June 30, 2020 | 13.82M |
| March 31, 2020 | 11.73M |
| December 31, 2019 | 11.09M |
| September 30, 2019 | 11.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Anixa Biosciences, Inc. | 1.258M |